Up to 80% of women develop fibroids by the age of 50. Fibroids are non-cancerous smooth muscle tumors. They are characterized ...

European researchers assessed the efficacy of oral ulipristal acetate (UA) — a selective progesterone-receptor modulator — for treating women in whom surgery for symptomatic fibroids was planned.

Allergan and Gedeon Richter's uterine fibroid treatment ulipristal acetate, has succeeded in a phase 3 trial ahead of a planned US filing next year. The companies announced positive results from ...

The research suggests that ulipristal acetate, the active ingredient in the morning after pill, could be used to replace mifepristone, one of the two drugs used in a common type of abortion.

The drugmaker used to sell another therapy for uterine fibroids in Europe called Esmya (ulipristal acetate), but its marketing authorisation was revoked in 2020 after a safety review that followed ...

Ulipristal acetate, a selective progesterone receptor modulator, combined with misoprostol resulted in pregnancy termination among nearly all participants in a small proof-of-concept study.